CD8A and neoplasm: Enriched lipid droplets impair oxaliplatin-induced immunogenic cell death, reduce cytotoxic factor release (e.g., IFN-γ), and promote CD8+ T cell exhaustion in the TIME, thereby enhancing tumor survival and driving liver metastasis and chemotherapy resistance [106].